Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XAIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XAIR
Wall Street analysts forecast XAIR stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.439
Low
6.00
Averages
6.00
High
6.00
Current: 0.439
Low
6.00
Averages
6.00
High
6.00
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
See More
Beyond Air Inc Reports Significant Financial Improvement
- Significant Revenue Growth: Beyond Air Inc reported a 107% year-over-year revenue increase to $7.7 million, driven by strong demand for LungFit PH, laying a solid foundation for future market expansion.
- Profitability Turnaround: The company achieved a $2 million improvement in gross profit, successfully reversing a $1.7 million loss from the previous year, marking a crucial milestone in profitability that boosts investor confidence.
- Cost Control in R&D and Operations: R&D expenses decreased by 39% to $10.2 million, while SG&A expenses fell by 27% to $19.1 million, demonstrating effective cost management strategies that contribute to overall financial health.
- Improvement in Net Loss: Although the net loss was $33.2 million, an improvement from $46.6 million the previous year, attention is needed on the potential impact of $21.6 million in long-term debt on financial flexibility.
See More
Beyond Air Reports 107% Revenue Growth for Fiscal Year 2026
- Significant Revenue Growth: Beyond Air reported a revenue of $7.7 million for fiscal year 2026, marking a 107% increase year-over-year, primarily driven by heightened demand for its LungFit PH product in both U.S. and international markets, showcasing the company's robust performance in the medical device sector.
- Quarterly Performance Improvement: The company achieved $1.9 million in revenue for the fourth quarter of fiscal 2026, reflecting a 66% year-over-year increase, indicating successful customer retention above 90% and the acquisition of new hospital clients, thereby solidifying its market position.
- Expanded Market Opportunities: The second-generation LungFit PH system is currently under FDA review, and if approved, it is expected to increase the addressable market in the U.S. to approximately $400 million and over $1 billion globally, highlighting the company's substantial future growth potential.
- Management Changes and Strategic Adjustments: Newly appointed CEO Robert Goodman is focused on aligning commercial execution with R&D resources, which is anticipated to propel the company into a new phase of commercial execution and enhance shareholder value.
See More
Beyond Air Reports FY Earnings with Significant Revenue Growth
- Earnings Report: Beyond Air's FY GAAP EPS of -$4.01 misses expectations by $0.24, indicating challenges in profitability despite significant revenue growth.
- Revenue Growth: The reported revenue of $7.7M represents a 108.1% year-over-year increase, although it fell short of expectations, highlighting strong market demand potential.
- Cash Position: As of March 31, 2026, the company reported cash, cash equivalents, restricted cash, and marketable securities totaling $17.3 million, providing a solid financial foundation for future initiatives.
- Future Guidance: The company projects revenue of $8 million for 2026, reflecting a 15% increase, while 2027 guidance ranges from $16-$18 million, indicating over 110% year-over-year growth at the midpoint, which includes the commercial launch of the second-generation LungFit PH system, demonstrating confidence in future growth prospects.
See More
Lucid, Beyond Air, and Conagra Shares Hit New Lows Amid Weak Guidance
- Lucid's Stock Decline: Lucid's shares fell to a 52-week low of $8.11 on Wednesday after issuing weaker-than-expected revenue guidance and announcing a $300 million stock offering, reflecting investor concerns about its profitability as the stock is down over 25% year-to-date.
- Beyond Air's Nasdaq Warning: Beyond Air received a Nasdaq compliance notice for trading below $1, hitting a 52-week low of $0.43 on Wednesday, down 28% year-to-date, indicating significant financial distress following the resignation of its CEO and the termination of a key transaction.
- Conagra's New CEO Raises Concerns: Following the appointment of a new CEO, Conagra's stock hit a 52-week low of $14.04 on Wednesday, down nearly 19% year-to-date, as analysts warn that inflationary pressures and global trade uncertainties will continue to weigh on earnings.
- Diverging Market Sentiment: Despite the declines in Lucid and Conagra, sentiment on Stocktwits remains 'extremely bullish' for Lucid, while Conagra's sentiment was slightly lifted by news of board members purchasing over $700,000 in shares, indicating investor hopes for a near-term rebound.
See More
Beyond Air CEO Steve Lisi Resigns, Robert Goodman Appointed
- Executive Change: Beyond Air's CEO Steve Lisi resigned effective March 27 after nine years of leadership, during which he oversaw the development and launch of the LungFit PH product, a move that may impact the company's strategic direction and market confidence.
- New CEO Appointment: The company appointed Chief Commercial Officer Robert Goodman as the new CEO immediately, who joined the board in 2025 and has served as Chief Commercial Officer since November 2025, indicating a continuity in commercial strategy and product development moving forward.
- Product Development Impact: Lisi's resignation may introduce uncertainty regarding the market performance of the LungFit PH product, especially following his leadership during its development phase, necessitating a reassessment of the company's product line and market strategy.
- Board Restructuring: This executive change may lead to a strategic restructuring of the board, with Goodman’s commercial background potentially bringing new market opportunities, but also facing integration challenges as the company adapts to new leadership.
See More
Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
See More
Beyond Air Inc Reports Significant Financial Improvement
- Significant Revenue Growth: Beyond Air Inc reported a 107% year-over-year revenue increase to $7.7 million, driven by strong demand for LungFit PH, laying a solid foundation for future market expansion.
- Profitability Turnaround: The company achieved a $2 million improvement in gross profit, successfully reversing a $1.7 million loss from the previous year, marking a crucial milestone in profitability that boosts investor confidence.
- Cost Control in R&D and Operations: R&D expenses decreased by 39% to $10.2 million, while SG&A expenses fell by 27% to $19.1 million, demonstrating effective cost management strategies that contribute to overall financial health.
- Improvement in Net Loss: Although the net loss was $33.2 million, an improvement from $46.6 million the previous year, attention is needed on the potential impact of $21.6 million in long-term debt on financial flexibility.
See More
Beyond Air Reports 107% Revenue Growth for Fiscal Year 2026
- Significant Revenue Growth: Beyond Air reported a revenue of $7.7 million for fiscal year 2026, marking a 107% increase year-over-year, primarily driven by heightened demand for its LungFit PH product in both U.S. and international markets, showcasing the company's robust performance in the medical device sector.
- Quarterly Performance Improvement: The company achieved $1.9 million in revenue for the fourth quarter of fiscal 2026, reflecting a 66% year-over-year increase, indicating successful customer retention above 90% and the acquisition of new hospital clients, thereby solidifying its market position.
- Expanded Market Opportunities: The second-generation LungFit PH system is currently under FDA review, and if approved, it is expected to increase the addressable market in the U.S. to approximately $400 million and over $1 billion globally, highlighting the company's substantial future growth potential.
- Management Changes and Strategic Adjustments: Newly appointed CEO Robert Goodman is focused on aligning commercial execution with R&D resources, which is anticipated to propel the company into a new phase of commercial execution and enhance shareholder value.
See More
Beyond Air Reports FY Earnings with Significant Revenue Growth
- Earnings Report: Beyond Air's FY GAAP EPS of -$4.01 misses expectations by $0.24, indicating challenges in profitability despite significant revenue growth.
- Revenue Growth: The reported revenue of $7.7M represents a 108.1% year-over-year increase, although it fell short of expectations, highlighting strong market demand potential.
- Cash Position: As of March 31, 2026, the company reported cash, cash equivalents, restricted cash, and marketable securities totaling $17.3 million, providing a solid financial foundation for future initiatives.
- Future Guidance: The company projects revenue of $8 million for 2026, reflecting a 15% increase, while 2027 guidance ranges from $16-$18 million, indicating over 110% year-over-year growth at the midpoint, which includes the commercial launch of the second-generation LungFit PH system, demonstrating confidence in future growth prospects.
See More
Lucid, Beyond Air, and Conagra Shares Hit New Lows Amid Weak Guidance
- Lucid's Stock Decline: Lucid's shares fell to a 52-week low of $8.11 on Wednesday after issuing weaker-than-expected revenue guidance and announcing a $300 million stock offering, reflecting investor concerns about its profitability as the stock is down over 25% year-to-date.
- Beyond Air's Nasdaq Warning: Beyond Air received a Nasdaq compliance notice for trading below $1, hitting a 52-week low of $0.43 on Wednesday, down 28% year-to-date, indicating significant financial distress following the resignation of its CEO and the termination of a key transaction.
- Conagra's New CEO Raises Concerns: Following the appointment of a new CEO, Conagra's stock hit a 52-week low of $14.04 on Wednesday, down nearly 19% year-to-date, as analysts warn that inflationary pressures and global trade uncertainties will continue to weigh on earnings.
- Diverging Market Sentiment: Despite the declines in Lucid and Conagra, sentiment on Stocktwits remains 'extremely bullish' for Lucid, while Conagra's sentiment was slightly lifted by news of board members purchasing over $700,000 in shares, indicating investor hopes for a near-term rebound.
See More
Beyond Air CEO Steve Lisi Resigns, Robert Goodman Appointed
- Executive Change: Beyond Air's CEO Steve Lisi resigned effective March 27 after nine years of leadership, during which he oversaw the development and launch of the LungFit PH product, a move that may impact the company's strategic direction and market confidence.
- New CEO Appointment: The company appointed Chief Commercial Officer Robert Goodman as the new CEO immediately, who joined the board in 2025 and has served as Chief Commercial Officer since November 2025, indicating a continuity in commercial strategy and product development moving forward.
- Product Development Impact: Lisi's resignation may introduce uncertainty regarding the market performance of the LungFit PH product, especially following his leadership during its development phase, necessitating a reassessment of the company's product line and market strategy.
- Board Restructuring: This executive change may lead to a strategic restructuring of the board, with Goodman’s commercial background potentially bringing new market opportunities, but also facing integration challenges as the company adapts to new leadership.
See More
